Jubilant Life Sciences gets DCGI nod for generic version of COVID-19 drug

The company#39;s subsidiary Jubilant Generics has received the approval from Drug Controller General of India (DCGI) to manufacture and market investigational drug remdesivir 100 mg/vial (lyophilized injection), Jubilant Life Sciences said in a late night filing to BSE.

from Moneycontrol Business News https://ift.tt/3hljpaS